drugset / Trial / NCT00888745
A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase I multicenter study that will be conducted in the United States and Europe.
Timeline
- Start
- 2009-05
- Primary completion
- 2010-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pateclizumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | pateclizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | pateclizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | pateclizumab | Monoclonal antibody | 5 mg/kg | Intravenous |